Skip to Main content Skip to Navigation
Journal articles

Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?

Abstract : We read with great interest the paper by Panes et al1 regarding the efficacy of early azathioprine (AZA) therapy in early Crohn’s disease (CD). The “AZathioprine for Treatment or Early Crohn’s disease in adults” (AZTEC) study was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial conducted in 31 Spanish hospitals over 3 years. The authors developed a randomized placebo-controlled trial in very early CD patients (<8 weeks of diagnosis) without bowel damage (symptomatic stenotic, penetrating, or perianal disease).
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-01687303
Contributor : Ngere Ul <>
Submitted on : Thursday, January 18, 2018 - 12:39:30 PM
Last modification on : Tuesday, October 13, 2020 - 10:46:52 AM

Identifiers

Collections

Citation

Peter Lakatos, Laurent Peyrin-Biroulet. Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?. Gastroenterology, WB Saunders, 2014, 146 (3), pp.867 - 868. ⟨10.1053/j.gastro.2013.11.053⟩. ⟨hal-01687303⟩

Share

Metrics

Record views

109